Metavention, Inc.

Tarsus Pharmaceuticals, Inc.

Medtronic Ireland Manufacturing Unlimited Company

Bobak Robert Azamian

Scott Bradley Vafai

Jonathan A Coe

Douglas Michael Ackermann, Jr

Shawn D Hickok

Joseph G Vehige

Scott Raymond Smith

Anthony Ciro Vrba

Douglas Michael Ackermann

James G Hansen

Kelly Justin McCrystle

Mark Wilson Ian Webster

Kevin Robert Hykes

Rossana Motta

Kathryn Elizabeth Empanger

Kenneth J Malomo

Michael David Perry

Eric Robert Reuland

Victor Kelvin Sun

Kelly Justin Mccrystle

Jonathan Allen Coe

Disclosed herein are compositions which can be used in methods for treating or preventing ophthalmic and dermatologic conditions in a human subject, including ocular surface conditions such as blepharitis or rosacea. The compositions can be topically administered directly to an eye, eyelid, or eyelashes of the patient for targeted local activity.

Isoxazoline parasiticide formulations

Disclosed herein are methods for treating or preventing ophthalmic and dermatologic conditions in a patient, including ocular surface conditions such as blepharitis. The methods can include topically administering directly to an ocular surface of one or more eyes of a patient in need of treatment thereof an effective amount of an isoxazoline parasiticide, formamidine parasiticide, or other active ingredient, formulated into an ophthalmic composition, the ophthalmic composition further comprising a pharmaceutically acceptable vehicle. Compositions are also disclosed.

Isoxazoline parasiticide formulations and methods for treating blepharitis

According to some embodiments, a method of treating a subject having diabetes or symptoms associated with diabetes is provided. The method includes delivering a neuromodulation catheter within a vessel (e.g., hepatic artery) having surrounding nerves that innervate the liver (e.g., sympathetic nerves of the hepatic plexus). The method may also include modulating (e.g., disrupting, ablating, stimulating) the nerves by mechanical compression, energy delivery, or fluid delivery.

Neuromodulation for metabolic conditions or syndromes

According to various embodiments, systems, devices and methods for modulating targeted nerve fibers (e.g., hepatic neuromodulation) are provided. The systems may be configured to access tortuous anatomy of or adjacent hepatic vasculature. The systems may be configured to target nerves within a wall of (e.g., within adventitia surrounding a lumen of) an artery or other blood vessel, such as the common hepatic artery.

Modulation of targeted nerve fibers

Ophthalmic compositions for treating ocularusing lotilaner formulations

Methods for treating demodex blepharitis using lotilaner formulations

Methods for treating ocularusing lotilaner formulations

Methods for treating ocular demodex using isoxazoline parasiticide formulations

Modulation of nerves innervating the liver

According to various embodiments, systems, devices and methods for modulating targeted nerve fibers (e.g., hepatic neuromodulation) or other tissue are provided. Systems, devices and methods for cooling energy delivery members are also provided. The systems may be configured to access tortuous anatomy of or adjacent hepatic vasculature. The systems may be configured to target nerves surrounding (e.g., within adventitia of or within perivascular space of) an artery or other blood vessel, such as the common hepatic artery.

Therapeutic tissue modulation devices and methods

Neuromodulation methods to alter glucose levels

Growing community of inventors

Newport Coast, CA, United States of America

Bobak Robert Azamian